Published in Med Pediatr Oncol on August 01, 2000
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov (2014) 2.64
Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem Biol (2011) 1.77
Retracted FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol (2005) 1.51
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis (2011) 1.51
Rhabdomyosarcoma in adolescent and young adult patients: current perspectives. Adolesc Health Med Ther (2014) 1.28
MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br J Cancer (2009) 1.06
Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther (2009) 1.05
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Front Oncol (2013) 1.02
Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts. Am J Pathol (2009) 1.00
Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res (2010) 0.98
Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma (2011) 0.96
Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems. Nat Rev Cancer (2015) 0.89
DUX4 differentially regulates transcriptomes of human rhabdomyosarcoma and mouse C2C12 cells. PLoS One (2013) 0.88
Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS One (2013) 0.86
Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma. Sarcoma (2012) 0.85
Advances in pediatric rhabdomyosarcoma characterization and disease model development. Histol Histopathol (2012) 0.85
Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis. Skelet Muscle (2012) 0.85
Rhabdomyosarcomas: an overview on the experimental animal models. J Cell Mol Med (2012) 0.84
High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Br J Cancer (2001) 0.83
Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma. Neoplasia (2013) 0.82
Targeting the p53 Pathway in Ewing Sarcoma. Sarcoma (2010) 0.82
Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma. Pediatr Blood Cancer (2015) 0.81
Analysis of molecular cytogenetic alteration in rhabdomyosarcoma by array comparative genomic hybridization. PLoS One (2014) 0.78
Differential cooperation of oncogenes with p53 and Bax to induce apoptosis in rhabdomyosarcoma. Mol Cancer (2006) 0.77
Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma. Pediatr Surg Int (2007) 0.76
MURC/cavin-4 Is Co-Expressed with Caveolin-3 in Rhabdomyosarcoma Tumors and Its Silencing Prevents Myogenic Differentiation in the Human Embryonal RD Cell Line. PLoS One (2015) 0.75
Uncovering metabolism in rhabdomyosarcoma. Cell Cycle (2016) 0.75
Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. Proc Natl Acad Sci U S A (1989) 7.19
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (1997) 7.07
MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. Science (1988) 6.78
mTOR and cancer therapy. Oncogene (2006) 3.07
Transformation by activated ras or fos prevents myogenesis by inhibiting expression of MyoD1. Cell (1989) 2.40
alpha-Amylase inhibitory activity of some Malaysian plants used to treat diabetes; with particular reference to Phyllanthus amarus. J Ethnopharmacol (2006) 2.38
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ (1990) 2.24
Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol (1999) 2.23
Analysis of the functional and host range-determining regions of the murine ectropic and amphotropic retrovirus envelope proteins. J Virol (1993) 2.12
Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther (2008) 2.10
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol (1995) 2.09
Amino acid-dependent control of p70(s6k). Involvement of tRNA aminoacylation in the regulation. J Biol Chem (1999) 2.08
Duplication of ATR inhibits MyoD, induces aneuploidy and eliminates radiation-induced G1 arrest. Nat Genet (1998) 2.04
Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol (2001) 2.03
Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science (1993) 1.99
Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer (2004) 1.92
Association study of neuregulin 1 gene with schizophrenia. Mol Psychiatry (2003) 1.89
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res (1999) 1.89
Amplification of the gli gene in childhood sarcomas. Cancer Res (1989) 1.84
Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum Mol Genet (2001) 1.83
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst (1998) 1.82
Fine structure DNA mapping studies of the chromosomal region harboring the genetic defect in neurofibromatosis type I. Am J Hum Genet (1989) 1.80
Association study of an SNP combination pattern in the dopaminergic pathway in paranoid schizophrenia: a novel strategy for complex disorders. Mol Psychiatry (2004) 1.79
Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res (1994) 1.75
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res (2001) 1.65
A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet (1987) 1.60
A method to reduce nasopharyngeal trauma from nasogastric tube placement. Anesth Analg (1994) 1.57
Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res (2001) 1.56
Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation. Am J Pathol (1994) 1.55
Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. J Pediatr Hematol Oncol (2000) 1.49
Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res (1999) 1.47
Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res (1987) 1.44
Monoclonal antibodies to the myogenic regulatory protein MyoD1: epitope mapping and diagnostic utility. Cancer Res (1992) 1.43
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol (1999) 1.41
Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol (1998) 1.41
Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res (2000) 1.41
Placental histomorphology in unexplained foetal loss with thrombophilia. Indian J Med Res (2009) 1.39
Artificial neural network to assist psychiatric diagnosis. Br J Psychiatry (1996) 1.39
Is non-woven fabric a useful method of packaging instruments for operation theatres in resource constrained settings? Indian J Med Microbiol (2015) 1.39
Human hepatic sinusoidal endothelial cells can be distinguished by expression of phenotypic markers related to their specialised functions in vivo. World J Gastroenterol (2006) 1.39
How safe is sugarcane juice? Indian J Med Microbiol (2007) 1.38
The risk of peripheral vein phlebitis associated with chlorhexidine-coated catheters: a randomized, double-blind trial. Infect Control Hosp Epidemiol (1997) 1.38
Bone sarcomas of the head and neck in children: the St Jude Children's Research Hospital experience. Cancer (2000) 1.37
Sex from W to Z: evolution of vertebrate sex chromosomes and sex determining genes. J Exp Zool (2001) 1.36
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res (2000) 1.35
Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. Am J Pathol (1990) 1.34
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
Anti-inflammatory activities of the methanol extracts and an isolated furanoditerpene constituent of Sphenocentrum jollyanum Pierre (Menispermaceae). J Ethnopharmacol (2005) 1.29
Mechanisms of resistance to rapamycins. Drug Resist Updat (2001) 1.28
Antiplatelet antibodies in cases of Glanzmann's thrombasthenia with and without a history of multiple platelet transfusion. Indian J Hum Genet (2009) 1.28
In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol (2000) 1.28
DNA structure and flexibility in the sequence-specific binding of papillomavirus E2 proteins. J Mol Biol (1998) 1.27
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res (2000) 1.27
p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res (2001) 1.26
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol (1997) 1.25
MSX1 inhibits myoD expression in fibroblast x 10T1/2 cell hybrids. Cell (1995) 1.24
Beneficial effects of yoga lifestyle on reversibility of ischaemic heart disease: caring heart project of International Board of Yoga. J Assoc Physicians India (2004) 1.23
Cysticercosis of the masseter: MRI and sonographic correlation. Dentomaxillofac Radiol (2015) 1.22
Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res (1987) 1.21
Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res (1979) 1.21
Orofacial pain - a presenting symptom of bisphosphonate associated osteonecrosis of the jaws. Br Dent J (2007) 1.19
Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest (1994) 1.19
Exenatide and acute pancreatitis. J Assoc Physicians India (2008) 1.18
Amplification of MDM2 inhibits MyoD-mediated myogenesis. Mol Cell Biol (1996) 1.17
Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer (2006) 1.17
Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res (1987) 1.17
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res (2000) 1.16
Drug resistance associated with altered DNA topoisomerase II. Adv Enzyme Regul (1993) 1.16
Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity. Phytomedicine (2004) 1.15
Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol (2001) 1.15
An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11. Cancer Gene Ther (2008) 1.15
Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res (1998) 1.14
An evaluation of the activity related to inflammation of four plants used in Thailand to treat arthritis. J Ethnopharmacol (2003) 1.14
Haloperidol concentrations elevated in Chinese patients. Psychiatry Res (1984) 1.14
Fibrinolysis, inhibitors of blood coagulation, and monocyte derived coagulant activity in acute malaria. Am J Hematol (1997) 1.13
Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res (2000) 1.12
Effects of cytotoxic agents on TdR incorporation and growth delay in human colonic tumour xenografts. Br J Cancer (1977) 1.12
Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci U S A (1991) 1.12
Coordinate regulation of two genes encoding gluconeogenic enzymes by the trans-dominant locus Tse-1. Proc Natl Acad Sci U S A (1988) 1.11
Tyrosinase inhibition by extracts and constituents of Sideroxylon inerme L. stem bark, used in South Africa for skin lightening. J Ethnopharmacol (2008) 1.11
Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. Hepatology (2001) 1.11
Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients. Oncogene (2007) 1.10
Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. Mol Pharmacol (2001) 1.10
Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. Clin Cancer Res (1999) 1.09
The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res (1999) 1.09
Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res (1981) 1.09
The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthetase covalent complex in human colon xenografts. Eur J Cancer Clin Oncol (1982) 1.07
Cytoplasmic sequestration of an O6-methylguanine-DNA methyltransferase enhancer binding protein in DNA repair-deficient human cells. Proc Natl Acad Sci U S A (1997) 1.07
In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease. J Pharm Pharmacol (2001) 1.07
Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital. J Clin Oncol (1999) 1.06
Effects of sex chromosome aneuploidy on male sexual behavior. Genes Brain Behav (2008) 1.05
Antimicrobial and antiinflammatory activities of extracts and constituents of Oroxylum indicum (L.) Vent. Phytomedicine (1998) 1.05